{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"22.43","upperLimit":"49.93","value":"35.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"51"}],"units":"Participants"}],"description":"ORR: percentage of participants with CR, CRc, CRh, CRi, and PR. CR, CRc, and CRh as defined in Outcome Measure 20 above. CRi: normalization of blast percentage (≤5%); normalization of neutrophil count (≥1000/μL) or platelet count (≥100,000/μL); absence of leukemic blasts; marked clearance of all skin lesions from baseline, residual hyperpigmentation or abnormality with BPDCN identified on biopsy (or no biopsy performed); nodal masses regression to normal size on CT; and spleen and liver not palpable and nodules disappeared. PR: Decreased by \\> 50% in blast percentage to 5%-25%; 50% to \\<100% clearance of all skin lesions from baseline; no new lesions in participants without lesions at baseline; ≥50% decrease in the sum of the product of the diameters (SPD) of up to 6 largest dominant masses, no increase in size of other nodes; ≥ 50% decrease in SPD of nodules (for single nodule in greatest transverse diameter), no increase in size of liver of spleen.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received IMGN632 via IV infusion on Day 1 of each 21-day cycle.","id":"OG000","title":"Total R/R BPDCN Participants - Schedule A: IMGN632 0.045 mg/kg"}],"paramType":"NUMBER","populationDescription":"mITT Population included all participants who were eligible based on the screening criteria and who received at least 1 dose of study drug. Here, 'Overall number of participants analyzed' = Total R/R BPDCN participants.","reportingStatus":"POSTED","timeFrame":"Up to approximately 81 months","title":"ORR As Assessed by Investigator in Total R/R BPDCN Participants","type":"SECONDARY","unitOfMeasure":"percentage of participants"}